Horton Susan, Gelband Hellen, Jamison Dean, Levin Carol, Nugent Rachel, Watkins David
School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.
Center for Disease Dynamics, Economics and Policy, Washington, DC, United States of America.
PLoS One. 2017 Aug 10;12(8):e0182951. doi: 10.1371/journal.pone.0182951. eCollection 2017.
Cost-effectiveness rankings of health interventions are useful inputs for national healthcare planning and budgeting. Previous comprehensive rankings for low- and middle- income countries were undertaken in 2005 and 2006, accompanying the development of strategies for the Millennium Development Goals. We update the rankings using studies published since 2000, as strategies are being considered for the Sustainable Development Goals.
Expert systematic searches of the literature were undertaken for a broad range of health interventions. Cost-effectiveness results using Disability Adjusted Life-Years (DALYs) as the health outcome were standardized to 2012 US dollars.
149 individual studies of 93 interventions qualified for inclusion. Interventions for Reproductive, Maternal, Newborn and Child Health accounted for 37% of interventions, and major infectious diseases (AIDS, TB, malaria and neglected tropical diseases) for 24%, consistent with the priorities of the Millennium Development Goals. More than half of the interventions considered cost less than $200 per DALY and hence can be considered for inclusion in Universal Health Care packages even in low-income countries.
Important changes have occurred in rankings since 2006. Priorities have changed as a result of new technologies, new methods for changing behavior, and significant price changes for some vaccines and drugs. Achieving the Sustainable Development Goals will require LMICs to study a broader range of health interventions, particularly in adult health. Some interventions are no longer studied, in some cases because they have become usual care, in other cases because they are no longer relevant. Updating cost-effectiveness rankings on a regular basis is potentially a valuable exercise.
卫生干预措施的成本效益排名是国家医疗保健规划和预算的有用依据。之前针对低收入和中等收入国家的综合排名是在2005年和2006年进行的,与千年发展目标战略的制定同步。随着可持续发展目标战略的审议,我们使用2000年以来发表的研究更新了这些排名。
对广泛的卫生干预措施进行了专家系统文献检索。以伤残调整生命年(DALYs)作为健康结果的成本效益结果换算为2012年美元。
93项干预措施的149项单独研究符合纳入标准。生殖、孕产妇、新生儿和儿童健康干预措施占干预措施的37%,主要传染病(艾滋病、结核病、疟疾和被忽视的热带病)占24%,这与千年发展目标的重点一致。超过一半的干预措施每DALY成本低于200美元,因此即使在低收入国家也可考虑纳入全民医保套餐。
自2006年以来排名发生了重要变化。由于新技术、改变行为的新方法以及一些疫苗和药物的价格大幅变化,重点已经改变。实现可持续发展目标将要求低收入和中等收入国家研究更广泛的卫生干预措施,特别是在成人健康方面。一些干预措施不再被研究,在某些情况下是因为它们已成为常规治疗,在其他情况下是因为它们不再相关。定期更新成本效益排名可能是一项有价值的工作。